Oxford Biomedica
Block Listing Application
Oxford, UK -
31 January 2024: Oxford Biomedica
plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy
CDMO, today announces that application
has been made to the Financial Conduct Authority and the London
Stock Exchange for admission to (i) the Premium segment of the
Official List and (ii) to trading on the London Stock Exchange for
a block listing of 300,000 ordinary shares of 50 pence each (the
"Ordinary Shares").
The Ordinary Shares are being reserved under a
block listing and will be issued from time to time pursuant to the
following schemes:
· OXB Long Term
Incentive Plan (LTIP) (250,000 Ordinary Shares);
· OXB Deferred
Bonus Plan (DBP) (50,000 Ordinary Shares);
It is expected that admission to the Official
List and the London Stock Exchange of the New Ordinary Shares will
become effective on 5th February 2024. The New Ordinary
Shares will rank pari passu in all respects with the Group's
existing ordinary shares in issue.
-Ends-
|
For further
information, please contact:
|
|
|
Oxford
Biomedica plc:
Natalie Walter, Company Secretary
|
Tel: +44 (0)1865 783 000
|
Oxford Biomedica (LSE: OXB) is a quality and
innovation-led cell and gene therapy CDMO with a mission to enable
its clients to deliver life changing therapies to patients around
the world.
One of the original pioneers in cell and gene
therapy, the Company has more than 25 years of experience in viral
vectors; the driving force behind the majority of gene therapies.
The Company collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV), adenoviral vectors, and other viral
vector types. Oxford Biomedica's world-class capabilities span from
early-stage development to commercialisation. These capabilities
are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has
locations across Oxfordshire, UK, Lyon and Strasbourg, France, and
near Boston, MA, US. Learn more at www.oxb.com, and follow us on
LinkedIn
and YouTube.
